Results
INSULIN SENSITIVITY
Between March 2022 and June 2022, 212 patients were screened, of which 156 were enrolled and randomized to receive PEG-Loxe (n = 104) or metformin (n = 52). Twelve (11.5%) patients in the PEG-Loxe group and five (9.6%) patients in the metformin group withdrew from the study. The main reasons for withdrawal were AEs and failure to follow-up (Consort flow diagram.The baseline characteristics of the patients are presented in Baseline characteristics of patients.BMI, body mass index; WC, waist circumference; VFA, visceral fat area; HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; HOMA2-%B, updated homeostatic model assessment for beta cell function; HOMA2-%S, updated homeostatic model assessment for insulin sensitivity; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; bpm, beats per minute; OAD, oral antidiabetic drug; IQR, interquartile range. Data are expressed as mean (SD), unless otherwise indicated.